[go: up one dir, main page]

PE20010744A1 - Uso de (2s,3s,5r)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol para el tratamiento de la obesidad - Google Patents

Uso de (2s,3s,5r)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol para el tratamiento de la obesidad

Info

Publication number
PE20010744A1
PE20010744A1 PE2000001089A PE0010892000A PE20010744A1 PE 20010744 A1 PE20010744 A1 PE 20010744A1 PE 2000001089 A PE2000001089 A PE 2000001089A PE 0010892000 A PE0010892000 A PE 0010892000A PE 20010744 A1 PE20010744 A1 PE 20010744A1
Authority
PE
Peru
Prior art keywords
morpholinol
dimethyl
obesity
difluorophenyl
treatment
Prior art date
Application number
PE2000001089A
Other languages
English (en)
Inventor
David Lee Musso
Jessica E Matthews
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9924275.2A external-priority patent/GB9924275D0/en
Priority claimed from GB0001861A external-priority patent/GB0001861D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20010744A1 publication Critical patent/PE20010744A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE AL USO DE (2S,3S,5R)-2-(3,5-DIFLUOROFENIL)-3,5-DIMETIL-2-MORFOLINOL DE FORMULA I, PARA TRATAR LA OBESIDAD, SUPRIMIR EL APETITO, CAUSAR LA PERDIDA DE PESO, PREVENIR EL AUMENTO DE PESO
PE2000001089A 1999-10-13 2000-10-11 Uso de (2s,3s,5r)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol para el tratamiento de la obesidad PE20010744A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9924275.2A GB9924275D0 (en) 1999-10-13 1999-10-13 Method for the treatment of obesity
GB0001861A GB0001861D0 (en) 2000-01-28 2000-01-28 Method for the treatment of obesity

Publications (1)

Publication Number Publication Date
PE20010744A1 true PE20010744A1 (es) 2001-07-23

Family

ID=26243494

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2000001089A PE20010744A1 (es) 1999-10-13 2000-10-11 Uso de (2s,3s,5r)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol para el tratamiento de la obesidad

Country Status (6)

Country Link
EP (1) EP1220673A2 (es)
JP (1) JP2003511410A (es)
AR (1) AR026022A1 (es)
AU (1) AU7750100A (es)
PE (1) PE20010744A1 (es)
WO (1) WO2001026641A2 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1414518A4 (en) 2001-08-08 2009-01-21 Kevin R Orton APPARATUS AND METHOD FOR ELECTRICAL CONDUCTION SLIMMING
WO2003097046A1 (en) 2002-05-17 2003-11-27 Duke University Method for treating obesity
PT2316456T (pt) 2003-04-29 2017-09-05 Orexigen Therapeutics Inc Composições para afetar a perda de peso compreendendo naltrexona e bupropion
WO2007067341A2 (en) 2005-11-22 2007-06-14 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
AU2007319472B2 (en) 2006-11-09 2013-01-17 Nalpropion Pharmaceuticals Llc Methods Of Administering Weight Loss Medications
JP2011506298A (ja) * 2007-12-05 2011-03-03 アストラゼネカ アクチボラグ 新規化合物ｉｖ
EP2303025A4 (en) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc METHOD FOR TREATING DIGITAL FAT SWITCHES
CA2726646A1 (en) * 2008-06-04 2009-12-10 Astrazeneca Ab New compounds vii
JP6196041B2 (ja) 2010-01-11 2017-09-13 オレキシジェン・セラピューティクス・インコーポレーテッド 大うつ病を有する患者において減量療法を提供する方法
RS60682B1 (sr) 2012-06-06 2020-09-30 Nalpropion Pharmaceuticals Llc Kompozicija za upotrebu u postupku lečenja prekomerne težine i gojaznosti kod pacijenata sa visokim kardiovaskularnim rizikom

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8924528D0 (en) * 1989-10-31 1989-12-20 Wellcome Found Heterocyclic pharmaceutical compounds,preparation and use
AU744261B2 (en) * 1997-04-24 2002-02-21 Merck Sharp & Dohme Limited Use of NK-1 receptor antagonists for treating eating disorders
WO1999025355A1 (en) * 1997-11-14 1999-05-27 Glaxo Group Ltd. Method of treating addiction to nicotine products
NZ529316A (en) * 1998-01-21 2004-05-28 Glaxo Group Ltd Pharmaceutically active morpholinol
MA26693A1 (fr) * 1998-09-28 2004-12-20 Glaxo Group Ltd Compositions pour administration par voie buccale

Also Published As

Publication number Publication date
AU7750100A (en) 2001-04-23
JP2003511410A (ja) 2003-03-25
WO2001026641A2 (en) 2001-04-19
EP1220673A2 (en) 2002-07-10
AR026022A1 (es) 2002-12-26
WO2001026641A3 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
MXPA04001037A (es) Derivados de n-fenilpirrol guanidina como ligandos del receptor de melanocortina.
NO20003233L (no) 4-hydroksykinolin-3-karboksamider og hydrazider som antivirale midler
CY1111050T1 (el) Φωσφονικα, μονοφωσφοναμιδικα, διφωσφοναμιδικα για την αγωγη των ιϊκων παθησεων
ATE384058T1 (de) Thiazolderivate
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
ATE297203T1 (de) Antithrombotische mitteln
HK1080470B (zh) 雜環化合物
HK1088845A1 (en) Use of parthenolide derivatives as antileukemic and cytotoxic agents
BRPI0417684A (pt) composto, composição farmacêutica, e, uso de um composto
GEP20074197B (en) 5ht2c receptor modulators
AU1676200A (en) Polyhydroxylated heterocyclic derivatives as anti-coagulants
PT1200412E (pt) Agentes anti-proliferativos de imidazole
ATE484508T1 (de) Furylverbindungen
ATE477256T1 (de) Thienylverbindungen
MXPA05007115A (es) Nuevos agonistas inversos del receptor cb 1.
DE60121461D1 (de) Kondensierte pyridoindolderivate
PE20010744A1 (es) Uso de (2s,3s,5r)-2-(3,5-difluorofenil)-3,5-dimetil-2-morfolinol para el tratamiento de la obesidad
PE20010541A1 (es) Uso de una composicion de benzimidazol para tratar el cancer
MY129310A (en) C-4 carbonate taxanes
SE9901077D0 (sv) Novel use
DK1373220T3 (da) Benzimidazoler, som er nyttige ved behandling af seksuel dysfunktion
EA200100141A1 (ru) Терапевтическая композиция на основе изофлавоноидов для применения в лечении опухолей цитотоксическими агентами
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
MXPA05006889A (es) Compuestos aromaticos como agentes anti-inflamatorios, inmunomoduladores y anti-proliferativos.
DE60001850D1 (de) Chalcon coumarine

Legal Events

Date Code Title Description
FA Abandonment or withdrawal